Pharmac has released a request for tender - for two cancer treatments

Lenvatinib can be used to treat kidney, thyroid and liver cancers.

If approved, it would be funded from December.

Second treatment, Bevacizumab is used on liver and ovarian cancer - and would be funded by next April.

Pharmac Chief Medical Officer, David Hughes, says offering them will have a wide effect, and could help hundreds of people with cancer.